Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AFF1
REST API REST API
Homo sapiens
AFF1 is differentially expressed in 335 experiments: 159 organism parts: cerebellum, liver, ... (157 more);, 242 disease states: normal, acute myeloid leukemia, ... (240 more);, 90 cell types 394 cell lines 47 compound treatments and 78 other conditions.
Synonyms MLLT2, AF4, PBM1, AF-4
Orthologs AFF1 (Gallus gallus)   ENSCING00000005955 (Ciona intestinalis)   Aff1 (Rattus norvegicus)   AFF1 (Bos taurus)   Aff1 (Mus musculus)   lilli (Drosophila melanogaster)   aff1 (Xenopus laevis)   AFF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of transcription, DNA-dependent, transcription, DNA-dependent, nucleus, positive regulation of transcription, DNA-dependent, sequence-specific DNA binding transcription factor activity
UniProt Accession D6RAU0, D6RIZ5, Q712L1, Q05D98, Q14C88, P51825, F5GXF9, E7EMC5, E7EMS5, E7ETI4, E9PBM3, F5H1V4
InterPro Term TF_AF4/FMR2
Search EB-eye ENSG00000172493
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-96
DU145
2
E-GEOD-20089, E-GEOD-17482
LNCaP
2
E-GEOD-14464, E-GEOD-14990
BT-474
2
E-GEOD-5823, E-GEOD-3529
HCC2157
2
E-MTAB-37, E-MTAB-62
388 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (48 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-GEOD-17186, E-MEXP-2360
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (75 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-MEXP-1327
Huntington's disease
3
E-AFMX-6, E-GEOD-3790, E-GEOD-1751
chronic myelogenous leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
control
2
E-GEOD-20602, E-GEOD-8121
236 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (31 experiments)

Factor Value U/D Experiments
none
4
10
E-MEXP-1958, E-GEOD-4668, E-TABM-868, E-GEOD-412, E-GEOD-2803, ... (14 experiments)
17beta-estradiol
4
3
E-GEOD-4668, E-GEOD-2292, E-GEOD-4006
control
2
E-GEOD-3284, E-GEOD-4006
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
M-CSF
1
E-GEOD-5099
phenol
1
E-GEOD-6907
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-MEXP-2280, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-GEOD-923, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.587 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM